(R)-Roscovitine

Potent and selective inhibitor of CDKs, More potent than olomoucine, Inhibits CDK1/cyclin B kinase (IC50 = 450 nM) , CDK2 (IC50 = 700 nM) and CDK5/p35 (IC50 = 160 nM), Inhibits M phase promoting factor (MPF) kinase activity, Arrests human fibroblasts in G1 phase, Antitumor compound, Activates the mitogen-activated protein kinase pathway, Targets both the p53 and NF-kappaB pathways, Has effects on calcium channel gating, Prevents DNA damage-induced cyclin A1 upregulation, Apoptosis inducer, As CYC202 in phase I clinical trials, Reviews.